• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20338 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     NIHR Health Technology Assessment programme Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2021     Norwegian Institute of Public Health (NIPH) Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice ivacaftor (Kalydeco®) extension of further conditions
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (systemic anaplastic large cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice dapagliflozin (Forxiga®) extension of further condition
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V] - Addendum]
2021     NIHR Health Technology Assessment programme Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA
2021     Scottish Health Technologies Group (SHTG) The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Self-application of an active motion splint within the treatment of ankle fractures]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchocopy with or without assisted robotics: use in lung nodules diagnosing process. Horizon Scanning Technologies]
2021     Scottish Health Technologies Group (SHTG) Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on the clustering of combination products and ghost clusters in GVS
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Satralizumab (neuromyelitis optica spectrum disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchoscopy: use in lung nodules placement markers and resection process. Horizon Scanning Technologies]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V]
2021     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on a potential candidate for conditional inclusion of entrectinib (Rozlytrek®) for solid tumours with NTRK gene fusion
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for complex procedures of the pancreas - Rapid Report]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on a potential candidate for conditional inclusion of larotrectinib (Vitrakvi®) for solid tumours with NTRK gene fusion
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia - Evidence report for the S3 guideline on non-restorative sleep/sleep disorders - Insomnia in adults]
2021     Austrian Institute for Health Technology Assessment (AIHTA) The economic and societal dimension of parental mental illness. Part 1: systematic review. Part II: economic evaluation framework
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Services and Delivery Research programme REhabilitation and recovery of peopLE with Aphasia after StrokE (RELEASE): Utilizing secondary data to enhance speech and language therapy interventions for people with aphasia after stroke
2021     Austrian Institute for Health Technology Assessment (AIHTA) ≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of formoterol/ glycopyrronium/ budesonide (Trixeo® aerosphere)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice multiple myeloma
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teriflunomide (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis (The EASI-SWITCH Trial)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Public Health Research (PHR) programme Safetxt:A randomised controlled trial of an intervention delivered by mobile phone messaging to reduce sexually transmitted infections (STI) by increasing sexual health precaution behaviours in young people.
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme HTA-SYMBAD StudY of Mirtazapine or carBamazepine for Agitation in Dementia
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ivermectin for COVID-19]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment oxybutynin intravesical solution (Vesolox®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Addendum to Commission A21-78]
2021     NIHR Health Technology Assessment programme Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2021     Agency for Care Effectiveness (ACE) MRI-US fusion targeted biopsy for diagnosis of prostate cancer
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice mexiletine (Namuscla®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in central nervous system tumors]
2021     Agency for Care Effectiveness (ACE) Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V. Addendum]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Teduglutide in short bowel syndrome]
2021     Agency for Care Effectiveness (ACE) Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [High frequency ablation of the endometrium using a mesh electrode in patients with menorrhagia]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2021     Agency for Care Effectiveness (ACE) Photodynamic therapy for treating non-melanoma skin tumours
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (treatment of neurofibromas in neurofibromatosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tolvaptan in autosomal dominant polycystic kidney disease]
2021     Agency for Care Effectiveness (ACE) Cochlear implants for treating adults with single-sided deafness (SSD)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tocilizumab in COVID-19 patients]
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Allocation of scarce resources in critical care units in a pandemic]
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     NIHR Health Technology Assessment programme Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89]
2021     NIHR Health Technology Assessment programme Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ambulatory oxygen therapy in COVID-19]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Services and Delivery Research programme Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) Surgery for carpal tunnel syndrome: a health technology assessment
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Risdiplam in spinal muscular atrophy]
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirbanibulin (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)